We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-12.93%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$591B
AUM Growth
-$94.6B
Cap. Flow
+$3.09B
Cap. Flow %
0.52%
Top 10 Hldgs %
20.46%
Holding
2,656
New
75
Increased
1,551
Reduced
819
Closed
97

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.72B
2
BKNG icon
Booking.com
BKNG
+$2.61B
3
RHT
Red Hat Inc
RHT
+$1.62B
4
JPM icon
JPMorgan Chase
JPM
+$1.43B
5
STT icon
State Street
STT
+$1.29B

Sector Composition

Rank Sector Weight
1 Healthcare 18.46%
2 Technology 17.53%
3 Financials 14.18%
4 Consumer Discretionary 14.02%
5 Communication Services 9.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SALM
2526
DELISTED
Salem Media Group, Inc. Class A Common Stock
SALM
$43K ﹤0.01%
20,450
QUMU
2527
DELISTED
Qumu Corp.
QUMU
$43K ﹤0.01%
22,750
+100
+0.4% +$234
AVXL icon
2528
Anavex Life Sciences
AVXL
$316M
$42K ﹤0.01%
26,728
-29,200
-52% -$66.3K
CAW
2529
DELISTED
CCA Industries, Inc.
CAW
$42K ﹤0.01%
19,247
ENZ
2530
DELISTED
Enzo Biochem, Inc.
ENZ
$37K ﹤0.01%
13,243
-100
-0.7% -$328
PHLT
2531
DELISTED
Performant Healthcare Inc
PHLT
$36K ﹤0.01%
15,900
ONCS
2532
DELISTED
OncoSec Medical Incorporated
ONCS
$36K ﹤0.01%
257
-441
-63% -$111K
OTIC
2533
DELISTED
Otonomy, Inc.
OTIC
$35K ﹤0.01%
18,700
LYTS icon
2534
LSI Industries
LYTS
$890M
$33K ﹤0.01%
10,325
SRNE
2535
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$31K ﹤0.01%
12,772
-60,454
-83% -$197K
ACGN
2536
DELISTED
Aceragen Inc
ACGN
$29K ﹤0.01%
+615
New +$70.7K
SUMR
2537
DELISTED
Summer Infant, Inc.
SUMR
$26K ﹤0.01%
2,722
FTR
2538
DELISTED
Frontier Communications Corp.
FTR
$26K ﹤0.01%
11,045
+196
+2% +$830
AREX
2539
DELISTED
Approach Resources Inc.
AREX
$25K ﹤0.01%
29,005
+200
+0.7% +$306
STRR
2540
DELISTED
Star Equity Holdings
STRR
$23K ﹤0.01%
792
PIR
2541
DELISTED
Pier 1 Imports, Inc.
PIR
$22K ﹤0.01%
3,656
-8,782
-71% -$240K
CLDX icon
2542
Celldex Therapeutics
CLDX
$3.52B
$21K ﹤0.01%
7,027
STRR
2543
Star Equity Holdings
STRR
$40.1M
$20K ﹤0.01%
1,460
ALTO icon
2544
Alto Ingredients
ALTO
$315M
$17K ﹤0.01%
20,000
-19,700
-50% -$32.5K
ASCMA
2545
DELISTED
Ascent Capital Group, Inc. Series A
ASCMA
$16K ﹤0.01%
42,277
EFOI icon
2546
Energy Focus
EFOI
$19.2M
$15K ﹤0.01%
711
+63
+10% +$2.72K
OPTT icon
2547
Ocean Power Technologies
OPTT
$54.1M
$15K ﹤0.01%
2,195
ADXS
2548
DELISTED
Advaxis Inc
ADXS
$11K ﹤0.01%
3,800
MMAT
2549
DELISTED
Meta Materials Inc. Common Stock
MMAT
$10K ﹤0.01%
92
+37
+67% +$5.6K
QUIK icon
2550
QuickLogic
QUIK
$238M
$8K ﹤0.01%
+743
New +$9.57K

Similar funds

T. Rowe Price Associates's Q4 2018 Portfolio in Review

As of Q4 2018, T. Rowe Price Associates held 2,656 positions worth $591B, down 14% from $685B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

T. Rowe Price Associates's Q4 2018 filing shows 75 new, 1,551 increased, 819 reduced and 97 closed positions. Its largest new stake was StoneCo: 28,883,228 shares worth $519M. The largest sale was Tesla, an estimated $2.72B.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.

  • T. Rowe Price Associates's largest Q4 2018 buy was StoneCo: 28,883,228 shares worth $519M.
  • T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q4 2018, an estimated $2.16B increase.
  • T. Rowe Price Associates's biggest Q4 2018 reduction was Tesla, cutting an estimated $2.72B.
  • T. Rowe Price Associates fully exited Aetna Inc in Q4 2018, selling an estimated $600M.
  • T. Rowe Price Associates's ten largest holdings make up 20% of its $591B portfolio in Q4 2018.
  • T. Rowe Price Associates opened 75 new positions and closed 97 in Q4 2018.
  • T. Rowe Price Associates's portfolio value fell 14% quarter-over-quarter to $591B.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.